EG23815A - Olanzapine dihydrated - Google Patents
Olanzapine dihydratedInfo
- Publication number
- EG23815A EG23815A EG98597A EG98597A EG23815A EG 23815 A EG23815 A EG 23815A EG 98597 A EG98597 A EG 98597A EG 98597 A EG98597 A EG 98597A EG 23815 A EG23815 A EG 23815A
- Authority
- EG
- Egypt
- Prior art keywords
- dihydrated
- olanzapine
- olanzapine dihydrated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2648696P | 1996-09-23 | 1996-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EG23815A true EG23815A (en) | 2007-08-19 |
Family
ID=21832112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EG98597A EG23815A (en) | 1996-09-23 | 1997-09-23 | Olanzapine dihydrated |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6251895B1 (da) |
| EP (1) | EP0831097B1 (da) |
| JP (1) | JP2001500878A (da) |
| KR (1) | KR100516088B1 (da) |
| CN (1) | CN1146567C (da) |
| AR (1) | AR009801A1 (da) |
| AT (1) | ATE221074T1 (da) |
| AU (1) | AU720366B2 (da) |
| BR (1) | BR9711541A (da) |
| CA (1) | CA2266444C (da) |
| CO (1) | CO4900057A1 (da) |
| CZ (1) | CZ299247B6 (da) |
| DE (1) | DE69714165T2 (da) |
| DK (1) | DK0831097T3 (da) |
| EA (1) | EA001881B1 (da) |
| EG (1) | EG23815A (da) |
| ES (1) | ES2180899T3 (da) |
| HK (1) | HK1009809A1 (da) |
| HU (1) | HU226167B1 (da) |
| ID (1) | ID21924A (da) |
| IL (1) | IL128956A0 (da) |
| MY (1) | MY125467A (da) |
| NO (1) | NO323979B1 (da) |
| NZ (1) | NZ334346A (da) |
| PE (1) | PE110298A1 (da) |
| PL (1) | PL194074B1 (da) |
| PT (1) | PT831097E (da) |
| RS (1) | RS49597B (da) |
| SI (1) | SI0831097T1 (da) |
| SV (1) | SV1997000079A (da) |
| TR (1) | TR199900639T2 (da) |
| TW (1) | TW518335B (da) |
| UA (1) | UA56184C2 (da) |
| WO (1) | WO1998011893A1 (da) |
| ZA (1) | ZA978512B (da) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA978515B (en) * | 1996-09-23 | 1999-03-23 | Lilly Co Eli | Intermediates and process for preparing olanzapine |
| US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
| CZ302367B6 (cs) * | 1998-09-30 | 2011-04-13 | Eli Lilly And Company | 2-Methylthienobenzodiazepinový prípravek |
| NZ519926A (en) * | 1999-12-28 | 2004-02-27 | Cipla Ltd | New polymorphic forms of olanzapine |
| US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
| IL154688A0 (en) * | 2000-08-31 | 2003-09-17 | Reddys Lab Ltd Dr | Hydrates of olanzapine and processes for the preparation thereof |
| US6740753B2 (en) | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
| CA2464306A1 (en) * | 2001-10-29 | 2003-05-08 | Dr. Reddy's Laboratories Ltd. | Olanzapine dihydrate-ii a process for its preparation and use thereof |
| ATE500258T1 (de) | 2002-05-31 | 2011-03-15 | Sandoz Ag | Verfahren zur herstellung von olanzapin form i |
| SI21270A (sl) | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalne oblike olanzapina in postopki za njihovo pripravo |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7323459B2 (en) * | 2002-12-24 | 2008-01-29 | Teva Pharmaceutical Industries Ltd. | Crystal forms, methods for their preparation and method for preparation of olanzapine |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| CA2546200A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
| AR047459A1 (es) | 2004-01-27 | 2006-01-18 | Synthon Bv | Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina) |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| ES2289974T1 (es) * | 2004-07-14 | 2008-02-16 | Shasun Chemicals And Drugs Limited | Metodo mejorado para producir la forma i de la olanzapina. |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE112005000641T5 (de) | 2004-09-06 | 2007-09-06 | Shasun Chemicals and Drugs Ltd., Chennai | Neues Verfahren zur Herstellung einer pharmazeutisch reinen polymorphen Form I von Olanzapin |
| US8877933B2 (en) | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| BRPI0518187A (pt) * | 2004-11-16 | 2008-11-04 | Elan Pharma Int Ltd | formulações de olanzapina em nanopartìcula injetáveis |
| DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| WO2006073886A1 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Olanzapine pamoate dihydrate |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| US7834176B2 (en) * | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
| US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
| EP2185559A1 (en) | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
| CA2724533C (en) * | 2008-07-24 | 2014-07-29 | Handa Pharmaceuticals, Llc | Stabilized atypical antipsychotic formulation |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| DK2731947T3 (da) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | Substitueret dimerisk quinazolin-derivat, fremstilling og andvendelse deraf i farmaceutiske sammensætninger til behandling af type i- og type ii-diabetes |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| JP2016027003A (ja) * | 2012-11-20 | 2016-02-18 | 大蔵製薬株式会社 | 長期間安定なオランザピンの水性医薬製剤 |
| EP3024464A1 (en) | 2013-07-26 | 2016-06-01 | Boehringer Ingelheim International GmbH | Treatment of myelodysplastic syndrome |
| JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害薬の医学的使用 |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5302716A (en) * | 1986-01-16 | 1994-04-12 | Schering Corporation | Fused benzazepines |
| US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
| ATE198891T1 (de) * | 1992-05-29 | 2001-02-15 | Lilly Co Eli | Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems |
| BR9508136A (pt) | 1994-06-28 | 1997-11-25 | Grace W R & Co | Bolsas tendo remendos protetores |
| EP0733368A1 (en) * | 1995-03-24 | 1996-09-25 | Eli Lilly And Company | Granule fomulation for olanzapine |
| EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| EG24221A (en) * | 1995-03-24 | 2008-11-10 | Lilly Co Eli | Process for preparing olanzapine |
| US5631250A (en) * | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
-
1997
- 1997-09-18 CA CA002266444A patent/CA2266444C/en not_active Expired - Fee Related
- 1997-09-18 TR TR1999/00639T patent/TR199900639T2/xx unknown
- 1997-09-18 PL PL97332541A patent/PL194074B1/pl unknown
- 1997-09-18 AU AU44241/97A patent/AU720366B2/en not_active Ceased
- 1997-09-18 HU HU0000065A patent/HU226167B1/hu not_active IP Right Cessation
- 1997-09-18 BR BR9711541A patent/BR9711541A/pt not_active IP Right Cessation
- 1997-09-18 CZ CZ0098999A patent/CZ299247B6/cs not_active IP Right Cessation
- 1997-09-18 ID IDW990059A patent/ID21924A/id unknown
- 1997-09-18 CN CNB971981213A patent/CN1146567C/zh not_active Expired - Fee Related
- 1997-09-18 WO PCT/US1997/016586 patent/WO1998011893A1/en not_active Application Discontinuation
- 1997-09-18 IL IL12895697A patent/IL128956A0/xx not_active IP Right Cessation
- 1997-09-18 JP JP10514881A patent/JP2001500878A/ja not_active Withdrawn
- 1997-09-18 EA EA199900325A patent/EA001881B1/ru not_active IP Right Cessation
- 1997-09-18 NZ NZ334346A patent/NZ334346A/en not_active IP Right Cessation
- 1997-09-18 RS YUP-154/99A patent/RS49597B/sr unknown
- 1997-09-18 KR KR10-1999-7002423A patent/KR100516088B1/ko not_active IP Right Cessation
- 1997-09-18 UA UA99031634A patent/UA56184C2/uk unknown
- 1997-09-22 DK DK97307379T patent/DK0831097T3/da active
- 1997-09-22 EP EP97307379A patent/EP0831097B1/en not_active Expired - Lifetime
- 1997-09-22 SI SI9730408T patent/SI0831097T1/xx unknown
- 1997-09-22 CO CO97055058A patent/CO4900057A1/es unknown
- 1997-09-22 AT AT97307379T patent/ATE221074T1/de active
- 1997-09-22 MY MYPI97004393A patent/MY125467A/en unknown
- 1997-09-22 PT PT97307379T patent/PT831097E/pt unknown
- 1997-09-22 ES ES97307379T patent/ES2180899T3/es not_active Expired - Lifetime
- 1997-09-22 SV SV1997000079A patent/SV1997000079A/es active IP Right Grant
- 1997-09-22 DE DE69714165T patent/DE69714165T2/de not_active Expired - Lifetime
- 1997-09-22 ZA ZA978512A patent/ZA978512B/xx unknown
- 1997-09-23 AR ARP970104361A patent/AR009801A1/es not_active Application Discontinuation
- 1997-09-23 US US08/935,883 patent/US6251895B1/en not_active Expired - Fee Related
- 1997-09-23 EG EG98597A patent/EG23815A/xx active
- 1997-09-23 PE PE1997000853A patent/PE110298A1/es not_active Application Discontinuation
-
1998
- 1998-02-27 TW TW086113833A patent/TW518335B/zh not_active IP Right Cessation
- 1998-09-21 HK HK98110803A patent/HK1009809A1/xx not_active IP Right Cessation
-
1999
- 1999-03-19 NO NO19991339A patent/NO323979B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG23815A (en) | Olanzapine dihydrated | |
| AP9700954A0 (en) | 6-ohenylpyridyl-2-amine derivatives | |
| ZA9710906B (en) | 6-Phenylpyridyl-2-amine derivatives | |
| IL125379A (en) | 19-nor-pregnene derivatives | |
| ZA974053B (en) | Alkylaminobenzothiazole and -benzoxazole derivatives | |
| HUP9701835A3 (en) | Vinyl-pirrolidinone-cephalosporin derivatives | |
| IL129418A0 (en) | 2-Methoxyphenylpiperazine derivatives | |
| IL125149A0 (en) | Pyrazol-4-yl-hetaroyl derivatives | |
| PL334558A1 (en) | Cephalosporinic derivatives | |
| HU9701479D0 (en) | N-benzylazolium derivatives | |
| ZA972591B (en) | Substituted 1-methyl-3-benzyluracils | |
| GB9604996D0 (en) | Benzodiazonine derivatives | |
| ZA9711235B (en) | Substituted pyrazol-3-ylbenzazoles | |
| GB9603226D0 (en) | Heterocyclyl-ergoline derivatives | |
| GB9600063D0 (en) | Guaridine derivatives | |
| IL130283A0 (en) | Polysaccharide-peptide derivatives | |
| IL125974A0 (en) | 2-thioxotetrahydropyrimidin-4-one derivatives | |
| GB9702049D0 (en) | Tetrahhydroisoquinoline derivatives | |
| HU9601036D0 (en) | Aryl-sulfonyl-hydroxamic-acid derivatives | |
| SG67992A1 (en) | N-benzylazolium derivatives | |
| ZA97172B (en) | Heterocycle-condensed morphinoid derivatives | |
| IL145864A0 (en) | Benzothiophenecarboxamide derivatives | |
| GB9610888D0 (en) | Aralkoxy-morphinan derivatives | |
| GB9603581D0 (en) | Amino-benzothiazole derivatives | |
| ZA972808B (en) | aminodihydropyridine derivatives |